EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS
https://doi.org/10.15690/vsp.v11i4.363
Abstract
Treatment of juvenile idiopathic arthritis (JIA) is one of the most important challenges in paediatric rheumatology. The results of the retrospective observational study of adalimumab (anti TNF human monoclonal antibodies) efficacy and safety in real clinical practice in treatment of 56 patients with JIA and primary or secondary resistance to other genetically engineered biological agents (48 — infiximab, 2 — etanercept, 5 — rituximab, 1 — abatacept) are demonstrated in this article. Adalimumab was administered hypodermically at the dosage of 40 mg per 2 weeks. The efficacy was assessed according to the criteria of ACR (pediatric). In 4 weeks of treatment in 100% of patients the 30% improvement was established, in 80% of patients — 50% improvement, and in 60% of patients — 70% improvement. In 25 weeks of treatment 30% improvement was documented in 100% of patients (56), 50% improvement — in 91% (51), 70% improvement — in 74% (41). Inactive stage of the disease was established in 24 weeks in 55% of children; in 1 year — in 85%; remission was established in 55% of children. No severe side effects were found. Therefore, the received data show that adalimumab is effective in patients with JIA, both with primary and secondary resistance to other biological agents.
About the Authors
E. I. Alexeeva
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Yekaterina Alekseyeva, Doctor of Medical Science, professor, head of rheumatologic department of the Scientific Center of Children’s Health of the Russian Academy of Medical Science, dean of pediatric department of the I.M. Sechenov First Moscow State Medical University
Russian Federation
Yekaterina Alekseyeva, Doctor of Medical Science, professor, head of rheumatologic department of the Scientific Center of Children’s Health of the Russian Academy of Medical Science, dean of pediatric department of the I.M. Sechenov First Moscow State Medical University
T. M. Bzarova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
S. I. Valieva
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
A. M. Chomakhidze
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. G. Chistyakova
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
N. I. Taibulatov
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
References
1. Furst D. E., Schiff M. H., Fleischmann R. M. et al. Adalimumab, a fully human anti tumor necrosis factor _ monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563–2571.
2. Weinblatt M. E., Keystone E. C., Furst D. E. et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial [published erratum appears in: Arthritis Rheum. 2003; 48: 855]. Arthritis Rheum. 2003; 48: 35–45.
3. Keystone E. C., Kavanaugh A. F., Sharp J. T. et al. Radiographic, clinical, and functional outcomes of treatment with Adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004; 50: 1400–1411.
4. Van de Putte L. B., Atkins C., Malaise M. et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508–516.
5. Mease P. J., Gladman D. D., Ritchhn C. T. et al. for the ADEPT Study Group Adalimumab for the treatment of patients with moderately to severely active psoratic arthritis results of a doubleblind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279–3289.
6. Lipsky P. E., van der Heijde D. M. F.M., St Clair E. W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.
7. Feldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.
8. Beutler B. The rote of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (57): 16–21.
9. Aikawa N. E., De Carvalho J. F., Silva C. A. et al Immunogenicity of anti-TNF agents in autoimmune diseases. Clin. Rev. Allerg. Immunol. 2010; 38 (2–3): 82–89.
10. Moreland L. W., Cohen S. B., Baumgartner S. W. et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 2001; 28: 1238–1244.
11. Breedveld F. C., Weisman M. H., Kavanaugh A. F. et al. The PREMIER study a multicenter, randomized, double blind clinical trial of combination therapy with Adalimumab plus methotrexate versus methotrexate alone or Adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26–37.
12. Burmester G. R., Manette X., Montecucco C. M. et al. Adalimumab alone and in combination with disease-modifying antirheu matic drugs for the treatment of rheumatoid arthritis in clinical practice the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. Published Online First 20 March 2007 (doi: 10.1136/ard. — 2006 066761).
13. Bombardieri S., Ruiz A. A., Fardellone P. et al. on behalf of ReAct Stusy Group. Effectiveness of Adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatol. Adv. Acc. Published May 15 2007 (doi: 10.1093/rheumatology/kem091).
14. Nicas S. N., Voulgan P. V., Alamanos Y. et al. Efficacy and safety of switching from Infliximab to Adalimumab a comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.
15. Bennett A. N., Peterson P., Zain A. et al. Adalimumab in clinical practice Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology. 2005; 44: 1026–1031.
16. Bijl A. E., Breedveld F. C., Antoni C. E. et al. Adalimumab (HUMIRA) is effective in treating patients with rheumatoid arthritis who previously failed infliximab [abstract SAT0062]. Ann. Rheum. Dis. 2005; 64 (III): 428.
17. Wick M. C., Ernestam S., Lmdblad S. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel) results from the STURE registry at Karohnska University Hospital Scand. J. Rheumatol. 2005; 34: 353–358.
18. Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint Bone Spine. 2004; 71: 601–603.
19. Haibel H., Rudwaleit M., Listing J. et al. Efficacy of Adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, doubleblind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008; 58 (7): 1981–1991.
20. Wijbrandts C. A., Klaasen R., Dijkgraaf M. G. еt al. Bone mineral density in rheumatoid arthritis patients 1 year after Adalimumab therapy: arrest of bone loss? Ann. Rheum. Dis. ARD Online First published on April 13, 2008 (doi: 10.1136/ard.2008.091611).
21. Kimel M., Cifaldi M., Chen N., Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J. Rheumatol. 2008; 35 (2): 206–215.
22. Лучихина Е. Л., Каратеев Д. Е., Насонов Е. Л. Первый опыт применения адалимумаба в России: предварительные результа- ты 24-недельного открытого исследования. Научно-практическая ревматология. 2008; 5: 59–63.
23. Lovell D., Ruperto N., Reiff A. et al. Long-term efficacy and safety of Adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR) and the 46th Annual meeting of the Association of Rheumatology Health Professionals (ARHP); 11/5/2011. Chicago, IL; USA. Abstract MIS (7190791).
24. Lovell Daniel J. et al. OLE DE 038: Long-term efficacy and safety of ADA for up to 6 years in patients with JIA. ACR1. Arthritis & Rheumatism. 2011; 63 (10, suppl.): abstract 265.
25. Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: efficacy and safety. Eur. J. Pediatr. 2011; 170: 157–167.
26. Dana M. R., Merayo-Lloves J., Schaumberg D. A., Forster C. S. Visual outcomes prognosticators in juvenile rheumatoid arthritisassociated uveitis. Ophthalmology. 1997; 104: 236–244.
27. Foster C. S. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Curr. Opin. Ophthalmol. 2003; 14: 395–398.
28. BenEzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89: 444–448.
29. Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of Juvenile Idiopathic Arthritis associated Uveitis — A Pilot Study. Abstract presented at: 8th Ann. Eur. League Against Rheumatism (EULAR 2007); June 13–16 2007. Barcelona, Spain. Abstract THU0483.
30. Schett G., Coates L. C., Ash Z. R. et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Research & Therapy. 2011; 13 (1): 4.
31. Liza B., Vazquez-Cobian, Flynn T., Lehman T. J. A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.
32. Tynjala P., Kotaniemi K., Lindahl P. et. al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008; 47 (3): 339–344. Epub 2008 Jan 31.
33. Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91 3: 274–276.
34. Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd. 2007; 224 (6): 526–531.
35. Foeldvari I., Nielsen S., Kummerle-Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. Nat. Clin. Pract. Rheumatol. 2007; 3 (11): 608–609.
36. Hogan M. J., Rimura S. J., Thygeson P. Signs and symptoms of uveitis: I. Anterior uveitis. Am. J. Ophthalmol. 1959; 47: 155–170.
37. Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010; 794.
38. Wallace C. A., Ruperto N., Gannini E. et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.
39. Ruperto et al. Long-term efficacy and safety of Adalimumab in 4–12 year old patients with juvenile idiopathic arthritis. Pediatric Rheumatol. 2011; 9 (1): 26.
40. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.
41. Mariette X. et al. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann. Rheum. Dis. 2005; 64: 262.
42. Wolbink G. J., Vis M., Lems W. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54 (3): 711–715.
Review
For citations:
Alexeeva E.I., Bzarova T.M., Valieva S.I., Denisova R.V., Isaeva K.B., Chomakhidze A.M., Chistyakova E.G., Sleptsova T.V., Mitenko E.V., Taibulatov N.I. EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS. Current Pediatrics. 2012;11(4):82-88. (In Russ.) https://doi.org/10.15690/vsp.v11i4.363
Views:
779
Email this article 
